News Category
Onco-Innovations is integrating manufacturing, preclinical, and regulatory activities for its lead cancer candidate ONC010, aiming to enable a potenti...
VERAXA Biotech appoints Raju Willener as CFO to strengthen financial leadership as it advances its BiTAC oncology pipeline, including promising early ...
Apimeds Pharmaceuticals US has hired IBN to enhance corporate communications, aiming to raise investor awareness of its subsidiary MindWave Innovation...
Regentis Biomaterials CEO Dr. Ehud Geller discusses the company's regenerative medicine platform and lead product GelrinC, which addresses a significa...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property portfolio and supports the development of a novel intranasal trea...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and an FDA...
Med-X is expanding its Nature-Cide natural pest-control brand and has obtained OMRI certification for key products, positioning itself for growth as i...
Telomir Pharmaceuticals' Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low concentrations, supporting further stu...
Quantum BioPharma received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis, a ...
GeoVax has entered a Memorandum of Agreement with CEPI to utilize the CEPI Centralised Laboratory Network for independent testing of clinical samples ...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has broadened its lipid-based delivery capabilities to help researchers engineer carriers that address stability, targeting, and cont...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics services, enabling researchers to overcome sample-pro...
A comprehensive review reveals that the tumor microenvironment actively reprograms natural killer cells into distinct subsets with specialized roles, ...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, signaling re...
Regentis Biomaterials reported first half 2026 financial results, highlighted progress in its pivotal Phase III trial for GelrinC, and received Europe...
Quantum BioPharma's Lucid-MS, a first-in-class drug that protects and rebuilds myelin, has received FDA clearance for a Phase 2 trial that could trans...
TransCode Therapeutics has named John Tattory as interim CFO following the retirement of Tom Fitzgerald, a move that could affect the company's financ...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its leadership as it advances its BiTAC® T-cell engager an...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, is moving into a Phase 2 trial for multiple sclerosis following FDA clearance of its IN...
Quantum BioPharma receives FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and rebuild myel...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and r...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, potentially boosting the compan...
Onco-Innovations' CMO discussed ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, and its planned first-in-human trial, underscoring th...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, marking a key step for a first-in-class therap...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving peak pressures of 100,000 atmospheres, signaling a critical ...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's lead candidate ENV-105, which targets CD105 to reverse d...
Nutriband's CEO attendance at the Nasdaq LaB summit signals the company's strategic positioning in the biotech investment community, highlighting its ...
Silo Pharma's participation in the IPAC-RS forum underscores its commitment to advancing SPC-15, a nose-to-brain drug delivery system for PTSD, with p...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its novel myelin repair candidate Lucid-MS marks a significant milestone that could shift the...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis candidate, has earned a new buy rating and high...
Helus Pharma's CEO will discuss its novel serotonergic agonists pipeline at a major investment conference, underscoring the company's Phase 3 and Phas...
GeoVax applauds the new global mpox vaccine stockpile initiative, highlighting its GEO-MVA candidate as a potential additional source to ensure sustai...
Voyageur Pharmaceuticals achieves a key milestone in its iodine production feasibility study with Bayer, receiving a $1 million payment and advancing ...
Greenland Mines (GRML) moves forward with its transformation into a critical minerals company by spinning off its biotech division in Q4, completing t...
VERAXA Biotech's appointment of Raju Willener as CFO signals its commitment to advancing its BiTAC platform and oncology pipeline with seasoned financ...
Scinai Immunotherapeutics refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its PinCell agreement, aiming to opti...
Onco-Innovations advances its oncology pipeline toward clinical trials by securing manufacturing readiness, IND-enabling progress, and funding, positi...
OS Animal Health's participation in the Moody Capital Solutions conference highlights its progress in developing OST-HER2, a promising immunotherapy f...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting myelin repair, signals a potential breakthrough in ...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a pivotal step toward addressing th...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Greenland Mines announces its transition to a focused rare earths and critical minerals company, including a planned biotech spin-off and acquisition ...
Quantum BioPharma's FDA clearance to begin Phase 2 testing of Lucid-MS marks a critical step toward a first-in-class multiple sclerosis therapy that t...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials for multiple sclerosis marks a significant step toward a novel therapy targe...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial highlights a novel approach targeting demyelination, offering new hope for MS patients an...
LGL Group's feature at the Moody Capital Solutions Disruptive Growth & Life Sciences Conference underscores its strategic initiatives in precision tim...
Interlink Electronics' participation in the Moody Capital conference underscores its strategic growth initiatives and reinforces its position as a lea...
